Palatin to Receive $500,000 Upfront

Entitled to Receive $3.0 Million on First Commercial Sale in Korea and Up to $37.5 Million in Sales Related Milestones plus Royalties on Net Sales

 

CRANBURY, N.J., Nov. 21, 2017 -- Palatin Technologies, Inc. (NYSE MKT: PTN; "Palatin") announced today that it has entered into a collaboration and license agreement with Kwangdong Pharmaceutical Co., Ltd. ("Kwangdong"), for exclusive rights to develop and commercialize bremelanotide for female sexual dysfunction (FSD) indications in the Republic of Korea.  Kwangdong, based in Seoul, Korea, is a leading Korean pharmaceutical company with annual sales of approximately $919 million in 2016. A New Drug Application (NDA) is anticipated to be filed with the U.S. Food and Drug Administration (FDA) in the first quarter of calendar year 2018.

2017-10-18 08:00 ET -  DarioHealth Bringing its Lightning®-enabled Version to the UK Market

 

CAESAREA, Israel, Oct. 18, 2017  -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, announced today that it received the CE Mark for its Lightning®-enabled version of the acclaimed Dario™ Blood Glucose Monitoring System. The news ensures that consumers, beginning in the UK market, will be able to receive the same quality user experience with DarioHealth on the latest Apple devices, including the brand-new iPhone 8.

 

The launch of Apple's smartphones with only a Lightning connector posed a unique challenge to the entire mobile ecosystem. With today's announcement, DarioHealth can now successfully offer its proprietary meter with either a 3.5mm headphone jack or Lightning connector.

2017-10-12 07:00 ET - WARSAW, Ind., Oct. 12, 2017  -- OrthoPediatrics Corp. (“OrthoPediatrics”), an orthopedic company focused exclusively on providing a comprehensive product offering to the pediatric orthopedic market, announced today the pricing of its initial public offering of 4,000,000 shares of its common stock at public offering price of $13.00 per share. In addition, OrthoPediatrics has granted the underwriters a 30-day option to purchase up to an additional 600,000 shares of its common stock at the public offering price, less the underwriting discount. The shares are expected to begin trading on the NASDAQ Global Market on October 12, 2017, under the ticker symbol “KIDS.” The offering is scheduled to close on October 16, 2017, subject to customary closing conditions.

 

Piper Jaffray and Stifel are acting as joint book-running managers, William Blair is acting as lead manager and BTIG is acting as co-manager for the offering.

TORONTO, Aug. 10, 2017 -  Medical Facilities Corporation ("Medical Facilities," "MFC," or the "Company") (TSX: DR), today reported its financial results for the three and six month period ended June 30, 2017. All amounts are expressed in U.S. dollars unless indicated otherwise.

 

Second Quarter 2017 Summary

Increased revenue by 25.2% to $96.1 million, from $76.7 million in Q2 2016, due to contributions from acquisitions and increases at existing facilities

Surgical cases increased by 14.9%, and revenue per case was up due to a higher proportion of complex cases

Increased EBITDA1 by 22.2% to $23.1 million from $18.9 million in Q2 2016

Paid monthly dividends of C$0.09375 per share, or C$1.125 per share on an annualized basis

Payout ratio1 of 72.4% as compared with 82.8% in Q2 2016